A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
第2相
早期終了
NCT04916002
| 対象疾患 | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Regeneron Pharmaceuticals |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 77 名 |
|---|
| 介入（薬剤） | vidutolimod, cemiplimab |
|---|
| 開始日 | 2021年11月30日 |
|---|
| 完了日 | 2024年10月31日 |
|---|
| 結果公開日 | 2025年12月5日 |
|---|
概要
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
Objective Response Rate (ORR)
Up to 31.5 Months · Percentage of participants
| Cohort A1: CMP-001+Cemiplimab for CSCC | 44.0 Percentage of participants |
|---|
| Cohort A2: CMP-001+Cemiplimab for CSCC | 5.3 Percentage of participants |
|---|
| Cohort B1: CMP-001+Cemiplimab for MCC | 46.2 Percentage of participants |
|---|
| Cohort B2: CMP-001+Cemiplimab for MCC | 6.3 Percentage of participants |
|---|
| Cohort D: CMP-001+Cemiplimab for BCC | 25.0 Percentage of participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。